Blog
RSS FeedPosted by Michael Wonder on 16 Sep 2021
PHARMAC funds tocilizumab to treat cases of COVID-19
16 September 2021 - PHARMAC is widening funded access to tocilizumab, an immunosuppressive drug used mainly to treat arthritis, to treat ...
Posted by Michael Wonder on 16 Sep 2021
PHARMAC funds new treatment for rheumatoid arthritis to support people impacted by tocilizumab stock shortage
16 September 2021 - PHARMAC has funded upadacitinib tablets as an alternative treatment for New Zealanders with severe rheumatoid arthritis, ...
Posted by Michael Wonder on 14 Sep 2021
Limiting the impact on Kiwis as API leaves the NZ market
14 September 2021 - PHARMAC is working hard to limit the impact on over 1 million Kiwis who currently take ...
Posted by Michael Wonder on 06 Sep 2021
New Zealand’s tocilizumab supply to be paused
6 September 2021 - PHARMAC has today announced that Roche, the global pharmaceutical company which provides tocilizumab, will not provide New ...
Posted by Michael Wonder on 31 Aug 2021
New Zealand Pharmaceutical Schedule - 1 September 2021 update
1 September 2021 - The September 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 26 Aug 2021
PHARMAC seeks feedback on a biosimilar brand of adalimumab being considered for funding
26 August 2021 - PHARMAC is considering awarding Principal Supply to a biosimilar brand of adalimumab (Amgevita) from 1 February ...
Posted by Michael Wonder on 23 Aug 2021
Dulaglutide receives Medsafe approval
23 August 2021 - Dulaglutide will be funded from 1 September 2021. ...
Posted by Michael Wonder on 17 Aug 2021
Information Act shows racism in PHARMAC’s decision-making
17 August 2021 - Paati Māori Co-leader, Debbie Ngarewa-Packer, has received information that blatantly outlines the inequity within PHARMAC and ...
Posted by Michael Wonder on 17 Aug 2021
PHARMAC to fund new cardiovascular medicine with amended Special Authority criteria
17 August 2021 - Pharmac has approved funding for a new medicine with substantial health benefits for around 75,000 New ...
Posted by Michael Wonder on 16 Aug 2021
PHARMAC must explain funding decisions
16 August 2021 - “A report this morning that all PHARMAC staff, rather than clinical experts or those with patient ...
Posted by Michael Wonder on 15 Aug 2021
PHARMAC invites entire staff to top secret drug ranking meetings
16 August 2021 - Highly confidential meetings where PHARMAC ranks the funding priority of potentially life-saving medicines are open to ...
Posted by Michael Wonder on 12 Aug 2021
Thousands of south Aucklanders could benefit from Medsafe approving new diabetes drug
12 August 2021 - Medsafe’s approval of a new drug for type 2 diabetes could dramatically change the lives of ...
Posted by Michael Wonder on 05 Aug 2021
Treasury wanted Labour to break all health election promises bar one
5 August 2021 - Treasury told the Government to kick its election promises like funding for PHARMAC, cochlear implants, and ...
Posted by Michael Wonder on 01 Aug 2021
Family says choice is life in Australia or death waiting for PHARMAC
2 August 2021 - A Tauranga couple is splitting up their family so their daughter can access treatment for spinal muscular ...
Posted by Michael Wonder on 31 Jul 2021
New Zealand Pharmaceutical Schedule - 1 August 2021
1 August 2021 - The August 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...